

GREATER LONDON AUTHORITY

[REDACTED]
(By email)

Our Ref: MGLA280720-9267

24 August 2020

Dear [REDACTED]

Thank you for your further correspondence which the Greater London Authority (GLA) received on 28 July 2020. Your request has been dealt with under the Freedom of Information Act 2000

You asked for:

Please could you clarify your answer: are you stating that no information whatsoever is held in regard to the event on October 10th 2014, including information internal to the teams you list above? For example, they might have retained some diary record of the event, a copy of the speech, the name of the team at BIS they were liaising with, or the detail as to whether the deputy mayor stood in at late notice for the mayor.

I am particularly interested to find additional information around this time that originated from BIS. They have retained the Minister's mailbox but details on this event are gone altogether, along with all email to Mayor and Deputy Mayor of London from 2014.

The attached circular from Hume Brophy gives some further information, including words from Kit Malthouse. If your records management system allows you to search by exact document, then a search against the attached PDF may bring up further information that I've been asking for. Note the speech references to money and Westminster: the DG Finance at BIS being the late Howard Orme CB.

Our response to your request is as follows:

Your previous requests (*MGLA270520-2906 and **MGLA280720-9267) focussed on the exchange of information between the GLA and external entities. We do not hold information within scope of these requests.

I understand from your recent request that you are now expanding the scope of your request to any information (including internal documentation) relating to the event of 10 October 2014. I can confirm that we do hold internal documentation relating to the event. Please find attached the information which we hold within scope of your request - a briefing from GLA officers to Kit Malthouse relating to the event.

Please note that some names of members of staff are exempt from disclosure under s.40 (Personal information) of the Freedom of Information Act. This information could potentially identify specific employees and as such constitutes as personal data which is defined by Article 4(1) of the General Data Protection Regulation (GDPR) to mean any information relating to an identified or identifiable living individual. It is considered that disclosure of this information would contravene the first data protection principle under Article 5(1) of GDPR which states that Personal data must be processed lawfully, fairly and in a transparent manner in relation to the data subject.

If you have any further questions relating to this matter, please contact me, quoting the reference at the top of this letter.

Yours sincerely


Information Governance Officer

If you are unhappy with the way the GLA has handled your request, you may complain using the GLA's FOI complaints and internal review procedure, available at:

<https://www.london.gov.uk/about-us/governance-and-spending/sharing-our-information/freedom-information>

Previous requests:

***MGLA270520-2906**

This request is made under the Freedom of Information Act.

For the period 1st April 2014 to 1st December 2014, please release all records held, including correspondence and details of telephone calls

- *between the Mayor of London, and his aides, **with the** Permanent Secretary, Department for Business, Innovation and Skills, and his private office.*
- *between the Mayor of London, and his aides, **with the** Director General Finance and Commercial, Department for Business, Innovation and Skills, and his private office.*

To assist in your searches, you may wish to note:

- *Martin Donnelly KCB CMG was the Permanent Secretary of BIS during this period*
- *the late Howard Orme CB was the Director General, Finance and Commercial of BIS during this period*
- *the Mayor of London was Mr Boris Johnson during this period*

****MGLA280720-9267**

Please could I additionally request: -

*Copies of all correspondence and any other information **between:***

- *the Mayor of London, Boris Johnson OR the Deputy Mayor of London, Kit Malthouse. This includes their aides, private offices, other advisors and similar.*

And

- *Permanent Secretary, Department for Business, Innovation and Skills (Sir Martin Donnelly) OR Director General Finance and Commercial (the late Howard Orme) OR Minister for Life Sciences at BIS (George Freeman MP), including prior to appointment. This includes their aides, private offices, other advisors and similar. For the same period in 2014.*

Briefing

What: Hume Brophy 6th Annual Healthcare Investor Conference
When: 16th October 2014, 12.30pm-6pm (your speaking slot is 5.40pm-6pm)
Where: Simmons & Simmons Offices, Citypoint, 1 Ropemaker Street, London EC2Y 9SS

To: Kit Malthouse, Deputy Mayor for Business and Enterprise, Chair of L&P
CC: Jeremy Skinner, [REDACTED]
From: [REDACTED]

1. Key attendees:

Hume Brophy have advised that 150 people from industry and the financial community will be attending the conference. The audience includes public and private pharmaceutical and medtech companies from Fresenius Medical Care, Shire Pharmaceuticals to smaller biotech companies such as Adaptimmune and Kymab. Approximately 50% of the audience are public and private investors such as: Polar Capital, UBS Asset Management, JP Morgan Asset Management, Index Ventures and Abingworth. Advisors from leading banks in the City will also be attending, including: Investec, JP Morgan, Jefferies, Numis and Piper Jaffray.

2. Your role:

The title of your 20-minute slot is: 'Healthcare & the City: Working Together'.

It is suggested that you may wish to speak for around 10 minutes, with Q&A for the remainder of the session.

3. The meeting/event and agenda:

12.30pm	Registration & Lunch
1pm	Welcome & Introduction
1.10pm	The Global Healthcare Opportunity Gerard van Odijk, former ex CEO of Teva Pharmaceuticals Europe
1.40pm	Importance of Life Sciences to the Economy Mr George Freeman MP, Parliamentary Under Secretary of State for Life Sciences
2.10pm	CEO Panel: Critical Factors for Building Successful Businesses Chaired by Mike Ward, Global Director of Content, Scrip Intelligence, Clinica,

The Pink Sheet & Datamonitor
Werner Lanthaler, CEO of Evotec
Chris Meredith, CEO of Advanced Medical Solutions
James Noble, CEO of Adaptimmune
Kieran Drain, CEO of Tyndall Institute
David Chiswell, Chairman of Kymab

- 3pm **Tea Break**
- 3.30pm **Communicating to Global investors: IR 3.0**
Oliver Maier, Head of Investor Relations, Fresenius Medical Care
- 4pm **Investment Opportunities in the Healthcare Sector**
Panel of public market investors and VCs discuss trends & opportunities across the healthcare sector
Chaired by Sam Fazeli, Bloomberg
Joe Anderson, Abingworth
Francesco de Rubertis, Index Ventures
Geraldine O’Keeffe, Life Science Partners
Andrea Ponti, GHQ Capital
Andy Richards, Life Sciences entrepreneur and investor
- 5pm **Fireside Chat: Attracting Generalist Investors to the Sector**
Charles Beazley, Former CEO of Nikko Asset Management
Dan Mahony, Polar Capital
- 5.40 pm **Healthcare & the City: Working Together**
Kit Malthouse, Deputy Mayor of London
- 6pm **Closing & Networking Drinks**

4. Pointers for your speech:

Overall message – to champion the strengths of life sciences in London and the GSE, set out ambition for London to be a leading centre for capital into life sciences, and position MedCity as the organisation that is working with the investment community to ensure that there are more investors in the space.

Introduction

- Delighted to be here today to see so many of you from the healthcare investment community. Also delighted that MedCity is supporting this afternoon’s conference.

MedCity overview

- The Mayor launched MedCity in April this year to maximise the enormous potential of the life sciences sector in London and the Greater South East.
- I believe that life sciences are one of the greatest and one of the most undersold strengths in this region.
- MedCity brings three global centres of medical research together - London, Oxford and Cambridge. Together, these centres already rival the greatest science cities such as Boston and San Francisco for life sciences research.

- Amazing breakthroughs have emerged from this 'golden triangle' of scientific innovation.
- From the discovery of the penicillin and DNA to the links between lung cancer and smoking, and the development of IVF – London, Oxford and Cambridge have been at the forefront of ground breaking research for decades.
- Just last week, the region's world class scientific discovery was recognised with the award of the Nobel Prize in Medicine to Professor John O'Keefe, who has made his career in one of our globally leading universities, University College London.
- This triangle is unique – offering the NHS, a large and diverse patient pool, access to medical records, and a growing and committed clinical trials infrastructure.
- It is the only region in the world which combines a world class financial centre, more than three centres of academic brilliance, a rich cultural offering that is global and diverse, and a life science sector that is thriving.
- The wealth of specialist expertise and facilities make this region an unbeatable place to do both business and research. And we are ambitious to turn our findings into therapies and technologies that will make a real difference to patients.

The challenge for the life sciences sector

- But more is needed if we are to collectively reap the health and economic benefits of our life science base.
- Put simply, the challenge is that we don't have enough investors in the life sciences space.
- There is more that we can do. We must work more closely with the City to highlight the range of investment opportunities that exists.
- MedCity is working with the investment community to address this, making the life sciences offer more accessible so that the world's investors can invest in our world class expertise and research.

Life sciences – an exciting industry

- Life sciences is a tremendously exciting industry that can deliver significant returns.
- The UK sector is in rude health, with recent data showing that we have more biotech drugs in the development pipeline than anywhere else in Europe – developing over 460 product candidates last year.¹
- In the first half of this year, the UK led Europe in the total amount of innovation capital raised – £734 million.²
- And we are seeing IPOs in the sector again, including Oxford's Circassia raising over £200 million in an IPO this summer.

¹ EY/BIA, Fundamental Strengths of the UK Ecosystem, State of the Nation 2014, published 7 October 2014

² EY/BIA, Fundamental Strengths of the UK Ecosystem, State of the Nation 2014, published 7 October 2014

- This is a sector which also gives investors the chance to get involved with companies that have the potential to genuinely transform lives, in areas such as cardiovascular disease, cancer, ageing and cognition, to name just a few.

MedCity's healthcare investment activity

- MedCity is currently working with the London Stock Exchange, along with the BIA and One Nucleus, to create and deliver a landmark conference on the future of healthcare investment.
- The aim of the conference is to demonstrate the fantastic opportunities that exist for investment in UK companies and to showcase the rich pipeline of companies that could IPO in the next year.
- The conference will take place on 29th January, and it will bring together specialist, generalist and institutional investors and brokers, along with leading life sciences companies.
- I hope that many of you will be able to join us at that event.

Conclusion

- There is still great unfulfilled economic potential in our life sciences sector. We want to see London be a leading centre for capital into life sciences, to ensure that we make the most of that potential.
- In that way we will benefit investors, enable more companies to grow to their full potential, producing more jobs and delivering more patient benefits than ever before.

[Take questions.]

5. Background:

The Hume Brophy Investor Healthcare Conference is now in its 6th year and attracts leading speakers from industry and the most influential investors in the healthcare sector, who will be sharing their views and providing an insight into future trends in the healthcare industry. Sponsored by Med City, the theme of this year's conference is: Investing in Future Growth: The Healthcare Opportunity.

Hume Brophy notes that: "The healthcare sector is going through one of the most successful periods for many years. There has been growing interest among investors, most notable in the US which is now spreading to Europe. The IPO market remains open and the pace of M&A continues. As we approach a major inflection point in innovation, how does the industry set expectations with all of the stakeholders - from investors to government to media to patients and to the public?"

Please see:

- Appendix 1 for further information about Hume Brophy Healthcare
- Appendix 2 for presentation briefings
- Appendix 3 for speaker biographies
- Appendix 4 for further information on MedCity's healthcare investment conference on 29th January 2015

Appendix 1 – About Hume Brophy Healthcare

Hume Brophy is an international communications firm specialising in PR, investor relations, public affairs, corporate and financial communications, and has a team of 70 consultants based in London, Brussels, Paris, Singapore and Dublin.

The Company has established a dedicated Healthcare Division to meet the growing and changing communication needs of companies operating in the global healthcare industry. We are working with clients across the whole healthcare landscape, from big pharma, medtech & diagnostics, generics, specialty pharma, healthcare services, biotech and healthcare charities.

Our twelve-strong healthcare specialist team are able to combine global industry knowledge and expertise in public relations, investor relations with government & EU regulatory affairs. This means that we can deliver unrivalled healthcare solutions to help clients communicate with the major decision makers and important influencers across the investment community, media, regulatory & legislative bodies, and major political parties and institutions in Europe. We understand the diverse nature of the healthcare industry and the roles that its constituents play.

Appendix 2 – Presentation Briefings

The Global Healthcare Opportunity

- **Dr Gerard van Odijk**, who previously held CEO and Senior positions at Teva and GSK, and is now Chairman and Non-Executive of a number of European companies, will share his unique perspective on the healthcare industry and the opportunities that the industry presents.

Importance of Life Sciences to the Economy

- **George Freeman MP** will be discussing the importance of the UK life science sector as a key driver of the economy.

CEO Panel: Critical Factors for Building Successful Businesses

The healthcare sector is going through one of the most successful periods for many years. These successful European CEOs will discuss and debate the current environments for companies, as well as what it takes to build successful businesses.

- Chaired by: **Mike Ward, Global Director of Content, Scrip Intelligence, Clinica, The Pink Sheet & Datamonitor**. Mike has been reporting on and analysing the healthcare industry for over 30 years.
- **David Chiswell, Chairman of Kymab**, co-founder and CEO of Cambridge Antibody Technology (CAT) which discovered the world's bestselling drug – Humira. Kymab is one of the leading lights in the UK biotechnology sector and recently raised \$40 million from Wellcome Trust and Gates Foundation.
- **Werner Lanthaler is CEO of Evotec**, a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies.
- **Chris Meredith is CEO of Advanced Medical Solutions** which develops and commercialises advanced woundcare products. Since joining AMS Chris has been instrumental in moving the business from a £1.1m loss in 2004, to a company today making £13 million profit off revenue of £60 million.
- **James Noble is CEO of Adaptimmune**, which is developing T-cell therapies and recently raised \$104m from US VCs.
- **Kieran Drain, CEO of Tyndall Institute**, has over thirty years' industrial experience in technology and business management in the US and Europe spanning diverse industrial segments.

Communicating to Global Investors: IR 3.0

- **Oliver Maier, Head of Investor Relations**, Fresenius Medical Care, will discuss the changing face of global investor relations and the importance of communicating to a broader stakeholder group. Oliver is the highest ranked IR professional in the global medtech sector.

Investment Opportunities in the Healthcare Sector

Europe's leading investors and analysts will provide an overview of their outlook on the market, as well as current and future trends that are driving investment in the healthcare sector. The panel will then answer questions on what they look for in companies, how they value companies and their views on the future of the healthcare industry.

- Chaired by: **Sam Fazeli, Bloomberg Intelligence**. Sam brings with him over 15 years of experience conducting equity research as a pharmaceutical analyst
- **Francesco de Rubertis is a Partner and co-founder of Life Sciences at Index Ventures**. Index Ventures is a leading venture capital firm with deep sector expertise based in London, San Francisco and Geneva.
- **Joe Anderson, Partner, Abingworth**, who has over 20 year's investment experience in the pharmaceutical and life science sectors. Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors.
- **Geraldine O'Keeffe, Life Science Partners**. Geraldine O'Keeffe has 20 years' experience in the healthcare industry and is focused on public market companies. LSP is one of Europe's largest and most experienced healthcare investment firms.
- **Andrea Ponti, GHO Capital**, has 29 years of investment banking experience, focusing on healthcare since 1996. He created both JP Morgan's and Goldman Sachs' European investment banking healthcare franchises.
- **Andy Richards, Life Sciences entrepreneur and investor**. Dr Andy Richards is a serial Biotechnology entrepreneur and business angel. Andy is one of the most renowned early stage investors in the sector.

Fireside Chat: Attracting Generalist Investors to the Sector

Charles Beazley and Dan Mahony will discuss the opportunities and potential in the healthcare industry, what drives investment and how to attract generalist investors into the sector.

- **Charles Beazley, Former CEO of Nikko Asset Management**, has 30 years' experience in investment management and has managed some of the world's largest investment firms in the USA, Europe and the Far East.
- **Dan Mahony manages healthcare investments at Polar Capital**. He has 25 years' experience in the healthcare sector across Europe and the US.

Healthcare & the City: Working Together

Kit Malthouse, Deputy Mayor of London, will discuss Healthcare & the City: Working Together.

Appendix 3 – Speaker Biographies

Gerard van Odijk, former ex CEO of Teva Pharmaceuticals Europe

Gerard van Odijk was President and Chief Executive Officer of Teva Europe from January 2006 until February 2012. From mid-2003 to December 2005, Dr Van Odijk was Senior Vice President and Area Director of GSK Northern Europe, and had previously held a variety of senior positions in Europe at Glaxo, GlaxoWellcome and GlaxoSmithKline serving in commercial and general management roles in France, the UK and The Netherlands. Dr Van Odijk currently serves as a non-executive director on the board of Bavarian Nordic A/S. He received his M.D. from the State University of Utrecht in 1987.

Mr George Freeman MP, Parliamentary Under Secretary of State for Life Sciences

George was elected to Parliament in May 2010 after a 15 year career in and around the Cambridge cluster supporting high growth businesses. For the seven years prior to being elected he was Founder and Chairman of the specialist translational medicine consultancy 4D Biomedical Ltd. Prior to that he was CEO of Cambridge start-up Amedis Pharmaceuticals, and before that the Director of Early Stage Ventures at Merlin Biosciences.

George has written and spoken widely on the potential of Britain's science and innovation economy to support a sustainable economic recovery and unlock huge trade and inward investment opportunities in fast emerging global markets.

Following the 2010 election he was appointed PPS to the Minister for Climate Change, Greg Barker MP and elected Chairman of the All-Party Parliamentary Group on Science & Technology in Agriculture. In 2011 he was appointed Government Adviser on Life Sciences to the Minister of State for Universities and Science, Rt Hon David Willetts MP. In this role he was closely involved in the development and implementation of the Government's Life Science Strategy announced by the PM in December 2011, and is actively working with UKTI to promote the UK Life Science sector including representing the UK Government on UKTI trade missions to the USA and Sweden.

David Chiswell, Chairman of Kymab, co-founded Cambridge Antibody Technology (CAT) in 1990 and was responsible for operational management, serving as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001 raising over £120m on the public markets. Since leaving CAT in 2002 he has focused on the development of early stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and as CEO of Nabriva Therapeutics (2009 to 2012).

Dr Chiswell currently serves as Albireo Pharma, and is Director of Nabriva Therapeutics. He is a past chairman of the UK BioIndustry Association (BIA) and in 2006 he was awarded the OBE by HM The Queen for services to the biotechnology industry.

Werner Lanthaler, CEO of Evotec

Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master's degrees from Harvard University, and holds a degree in Psychology.

James Noble, CEO of Adaptimmune

James has over two decades of experience in biotechnology, having served on public and private boards of companies in the UK, the USA and Germany. At the executive level, he served as CFO of British Biotech plc from 1990 to 1997, where he was responsible for raising over £300 million in equity capital from the UK, USA, Japan and continental Europe and for the simultaneous listing in London and on NASDAQ. James was the CEO of Avidex (the predecessor company of Adaptimmune) from 2000 and 2006 when the company was sold to MediGene AG, where James joined the supervisory board. James was responsible for the spin-outs of both Immunocore and Adaptimmune from MediGene in 2008 and served as CEO of both. In March 2014, James relinquished his position as CEO of Immunocore in order to focus exclusively as CEO of Adaptimmune, although he remains a non-executive director of Immunocore. At the non-executive level, James has served on a number of boards including: Oxford Glycosciences plc, Curagen Inc, PowderJect Pharmaceuticals plc and was the founding chairman of Biovex. He is currently Deputy Chairman at GW Pharmaceuticals plc, a NASDAQ and AIM-listed biotech company.

Prior to his involvement in the biotech industry, James graduated from Oxford in 1980 and qualified as a chartered accountant with Price Waterhouse in 1983. He then spent seven years at Kleinwort Benson Limited, reaching Director in 1990.

Sam Fazeli, Bloomberg Intelligence

Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Professional service at BI. Sam specializes in European pharmaceuticals and biotechnology. Sam brings with him over 15 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, Sam was a research scientist for seven years. Sam has been ranked a top analyst by both the U.K. and Pan-European Exel surveys. He received a bachelor's of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.

Francesco de Rubertis, Index Ventures

Francesco is a Partner and co-founder of the firm's life sciences practice. He joined Index in 1998 and has overseen all of the life sciences investment of the firm. Present and past Index portfolio companies include: Versartis (VSAR), Egalet (EGLT), Genmab A/S (Coph: GEN.CO), CellZome Inc. (sold to GlaxoSmithKline), Molecular Partners A/G, Aegerion Inc. (Nasdaq: AEGR), Addex Pharmaceuticals SA (Swx: ADXN), PanGenetics B/V (sold to Abbott Pharmaceuticals), Micromet Inc. (sold to Amgen), Biozell SpA (sold to Cosmo Pharmaceuticals) and Parallele Inc. (sold to Affymetrix). Francesco has served on most of these boards. Prior to joining Index, Francesco was involved in post-doctoral research in genetics at the Whitehead Institute, Massachusetts Institute of Technology (MIT). He is also the author of several publications in international scientific journals. Francesco has a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva. He is a CFA charter holder, and is a member of the Strategic Advisory Board of the University of Geneva.

Joe Anderson, Abingworth

Dr Joe Anderson, Partner at Abingworth, has over 20 years investment experience in the pharmaceutical and life science sectors. He joined Abingworth in 2004, where he leads Venture Investments Public Equities (VIPEs) in the US and EU. He also led the establishment of Abingworth BioEquities and is a Director of that fund. Joe was previously at Commonwealth Bank of Australia (First State) in London, where he was Head of Global Healthcare Equities and Portfolio Manager for the Health and Biotechnology fund, which he founded. Prior to this, he was an Equities Analyst at investment bank, Dresdner Kleinwort Benson, where he covered the

Pharmaceuticals sector. Following a PhD in Biochemistry, Joe joined the Wellcome Trust, a leading medical foundations, where he led the Strategy Unit for 8 years. His current and past public company directorships include Algeta (acquired by Bayer), Amarin Corporation plc (Nasdaq), Epigenomics and Cytos Biotechnology.

Geraldine O’Keeffe, Life Science Partners

Geraldine O’Keeffe joined LSP in 2008. She became a Partner of the firm in 2010. Geraldine’s prime focus and responsibility within LSP is to invest in listed securities. Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. In that position, she researched a wide range of innovative life sciences companies, both in Europe and the US. Geraldine brings strong analytical and investment skills to the LSP team. Before joining the financial community, she worked within the life sciences industry for a number of years, gaining first-hand product development experience in a commercial setting. Prior to working in the industry, she lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a very strong scientific background, including a Bachelor’s degree in Biochemistry and Microbiology from University College Cork and a Master’s degree in Biotechnology from University College Galway. She also conducted post-graduate research, inter alia at the prestigious Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. In addition, Geraldine is also a graduate of The Dublin School of Business. Geraldine lives in Amsterdam with her husband and two children.

Andrea Ponti, GH0 Capital

Andrea has 29 years of investment banking experience, focusing on healthcare since 1996. He created both JP Morgan’s and Goldman Sachs’ European investment banking healthcare franchises, advising on some of the most significant Mergers and Acquisitions for leading pharmaceutical, medical device and hospital companies but also advising emerging companies and private equity on M&A and debt or equity financing. Over the last five years he was Vice Chairman of European Investment Banking and Global co-head of Healthcare at J.P. Morgan. Prior to that Andrea was at Goldman Sachs, where he was Partner, Managing Director, Head of European Healthcare, Consumer and Retail and also Co Global Head of Healthcare and covered a variety of roles during his time at the firm including member of the firm-wide Commitments Committee. Andrea sits on the board of Cell Medica and holds a BA in Economics with Highest Honours from the University of North Carolina at Chapel Hill.

Andy Richards, Life Sciences entrepreneur and investor

Dr Andy Richards is a serial Biotechnology entrepreneur and business angel. He is currently Chairman of Altacor, Novacta Abcodia and Ixico and is a director of Arecor, Summit Corp plc, PsychologyOn-line, Cancer Research Technology (commercial arm of CR-UK) and Babraham Bioscience Technology.

Andy is a Cambridge graduate with a PhD in Chemistry who spent his early career with ICI (now AstraZeneca) and with PA Technology. He was a founder of Chiroscience and an executive director through to the sale to Celltech in 1999. Since that time he has been founding and investing in new Cambridge based biotechnology companies including several of those listed above as well as Arakis, Geneservice, Cambridge Biotechnology Ltd, Amedis Pharmaceuticals, Sirius Pharmaceuticals, Daniolabs and Pharmakodex, all of which were recently sold.

He is a council member of the Biotechnology and Biological Sciences Research Council (BBSRC), a founder member of the Cambridge Angels, the founding Chairman of BIA Bioangels and an advisor to Vectura plc, CUTECH, 4D-biomedical and Toscana Life Sciences.

Charles Beazley, Former CEO of Nikko Asset Management

Charles was previously the CEO Nikko Asset Management in Europe and the Middle East. He is well known within the industry for his expertise in the field of alternative and specialist investment management. Prior to Nikko, Charles was a Board Director of Gartmore PLC

London, Head of Global Institutional and Alternative Investments and Chairman of Gartmore Japan. His experience includes 13 years at Merrill Lynch in Both Capital Markets and Asset Management, where he was a Managing Director. Charles has lived and worked in the UK, France and the US where he spent seven years. Prior to that he was at Orion Royal Bank and began his career at Lazard in 1984 in fixed income portfolio management. He graduated from the School of Slavonic and East European Studies at London University with his BA and subsequently his Masters in 1983.

Dan Mahony, Polar Capital

Dan joined Polar Capital to set up the Healthcare Investment team in 2007. He has more than 12 years' investment experience in the healthcare sector, with over 3 years as a portfolio manager and 9 years as a sell-side analyst. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, which covered the European biotechnology, medical technology and healthcare services industries. Dan was ranked second in the Institutional Investor Magazine All-Europe Research Team survey in 2003. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Dan worked as a research scientist for 7 years with the majority of his time at Schering Plough Corporation in California.

Dan acts as co-manager of the Polar Capital Healthcare Growth and Income Trust and the Polar Capital Healthcare Opportunities Fund alongside Gareth Powell. He has primary responsibility for medical devices, diagnostics, and healthcare services company sectors on a global basis. Dan received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991.

Chris Meredith, CEO of Advanced Medical Solutions

Mr Meredith was appointed Group Chief Executive Officer in January 2011. He joined AMS as Group Commercial Director in July 2005 following a successful 18-year career in international healthcare sales, marketing and business development. Since joining AMS Chris has been instrumental in moving the business from a £1.1m loss in 2004, to a company today making £13 million profit off revenue of £60 million. His experience prior to joining AMS covered business to business contract manufacturing, product development and clinical research, as well as branded product sales, all within the medical device, pharmaceutical or consumer healthcare markets. He was appointed Managing Director of Advanced Woundcare in February 2008 and in January 2010 he became Chief Operating Officer for the Group. Mr Meredith has previously held senior positions at Smiths Industries, Cardinal Health, Banner Pharmacaps, and Aster Cephac.

Kieran Drain, CEO of Tyndall Institute

With over thirty years' industrial experience in technology and business management in the US and Europe spanning diverse industrial segments, Dr Kieran Drain was appointed CEO of Tyndall National Institute, Ireland, in January 2013.

A specialist in the management of R&D and in the commercialisation and introduction of new technologies to market, Dr Drain joined Tyndall from his role as Vice President and General Manager of the Lighting and Display Technology Division of Rambus Inc, Ohio.

Prior to Rambus, Dr Drain served as President and CEO of venture-funded NanoGram Corporation (now a division of Teijin Japan); Vice President and General Manager for the Global Performance Polymers Division of Avery Dennison Corporation (NYSE:AVY). Prior to his role at Avery Dennison, he managed Ciba Specialty Chemicals business (now Huntsman Advanced Materials) in photopolymers and electronics in North America and Ciba's polymer division corporate technology developments for almost a decade in both the US and Europe. Previously, he was the head of R&D for the Formulated Materials and Electronics business unit at Ciba Geigy in Switzerland and led electronics product development for Loctite Corporation (now Henkel) in the US, having begun his career with Loctite Ireland as a Research Chemist.

Dr Drain holds PhD (Industrial Chemistry), MSc (Polymer Chemistry) and BSc (Pharmacy) degrees from Queen's University Belfast and is a Fellow of the Royal Society of Chemistry, United Kingdom. He also holds an MBA in Finance and Accounting from Regis University, Denver, Colorado.

Oliver Maier, Senior VP Investor Relations & Corporate Communications, Fresenius Medical Care

Oliver Maier has been Head of Investor Relations & Corporate Communications with Fresenius Medical Care since October 1999. Before joining Dresdner Kleinwort Benson, where he worked as senior analyst for the European Pharmaceuticals sector from 1996 – 1999, he worked as analyst with Schröder Münchmeyer Hengst in Frankfurt.

Appendix 4 – MedCity’s Healthcare Investment Conference, January 2015

MedCity is working with the London Stock Exchange (LSE) along with the BIA and One Nucleus to create and deliver a landmark conference on the future of healthcare investment.

The event will take place at the LSE on 29th January 2015. The attendees will be around 200 people with a mix of investors and companies. It will be free to attend but by invitation only. There will be a mix of keynote speakers, panels of investors and company presentations, with strong support from the broking and investment banking community.

MedCity has brought together the group of organisers and the timing is deliberate. The US San Francisco JP Morgan conference will have taken place around two weeks before. This will be an opportunity to focus on the UK and how the public markets can play a prominent and exciting role in contributing to the success of our thriving life sciences base. The City of London needs to be at the very heart of this activity.